Fatty Liver Disease: Diagnosis and Stratification

Area of Science:

• Hepatology
• Internal Medicine
• Public Health

Background:

• Nonalcoholic fatty liver disease (NAFLD) affects 25% of the global population, representing a significant public health concern.
• The disease spectrum ranges from simple steatosis to advanced fibrosis and cirrhosis, a leading cause for liver transplantation in specific demographics.
• NAFLD is strongly associated with increased risk of cardiometabolic diseases.

Purpose of the Study:

• To review current diagnostic and risk stratification methods for NAFLD.
• To highlight the importance of addressing cardiometabolic risk in NAFLD patients.
• To discuss management considerations for NAFLD, including advanced stages like cirrhosis.

Main Methods:

• Literature review focusing on NAFLD diagnosis, risk stratification, and management.
• Synthesis of data on noninvasive assessment tools for liver disease.
• Analysis of the link between NAFLD and cardiometabolic disease.

Main Results:

• Noninvasive tools have significantly improved NAFLD diagnosis.
• NAFLD patients face elevated risks for cardiometabolic conditions.
• Risk stratification is essential for tailoring therapeutic approaches.

Conclusions:

• Effective diagnosis and risk stratification are key to managing the NAFLD epidemic.
• Integrated management addressing both liver and cardiometabolic health is necessary.
• Special attention is required for patients with NAFLD-related cirrhosis.